Tamoxifen vs Turinabol
FDA Approved vs Moderate Research
avoid Mechanism-based · 64% Both Tamoxifen and Turinabol carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently.
Molecular Data
Tamoxifen Turinabol
Weight 371.51 Da 334.88 Da
Half-life ~5-7 days ~16 hours
Type Triphenylethylene-derived selective estrogen receptor modulator 17-alpha-alkylated anabolic-androgenic steroid (C20H27ClO2)
Key Benefits
Tamoxifen
01 Blocks estrogen receptor signaling in breast tissue, preventing and treating gynecomastia
02 Stimulates LH and FSH production by antagonizing hypothalamic estrogen receptors
03 Restores endogenous testosterone production during post-cycle therapy
04 Partial estrogen agonist activity in bone preserves bone mineral density
05 Extremely long half-life allows for flexible dosing schedules
06 Decades of clinical use with a well-characterized safety and efficacy profile
07 Oral administration with no injections or reconstitution required
Turinabol
01 Promotes lean, dry muscle gains without water retention or bloating
02 Does not aromatize to estrogen, eliminating risk of gynecomastia and estrogen-related side effects
03 Favorable anabolic-to-androgenic ratio, reducing androgenic side effects relative to muscle-building potential
04 Enhances muscular endurance and recovery through increased red blood cell production
05 Increases strength without significant body weight gain, beneficial for weight-class athletes
06 Improves creatine phosphate resynthesis, supporting repeated high-intensity efforts
07 Relatively mild androgenic profile compared to most oral anabolic steroids
08 Produces slow, steady, maintainable gains rather than rapid temporary increases
Side Effects
Tamoxifen
Hot flashes and night sweats
Nausea or gastrointestinal discomfort
Mood swings, irritability, or emotional lability
Fatigue during initial weeks of use
Headache
Turinabol
Hepatic stress with elevated liver enzymes (ALT, AST) -- moderate severity, dose- and duration-dependent
HDL cholesterol suppression (significant, often 30-50% reduction)
LDL cholesterol elevation
Suppression of endogenous testosterone production via HPG axis negative feedback
Mild gastrointestinal discomfort or nausea
Back pumps (lower back tightness during exercise, common with 17-alpha-alkylated compounds)
Oily skin and mild acne
Decreased appetite in some users
Contraindications
History of deep vein thrombosis, pulmonary embolism, or other thromboembolic events
Known hypersensitivity to tamoxifen citrate or any excipients
Concurrent warfarin or coumarin-type anticoagulant therapy (increased bleeding risk)
Pregnancy or planned pregnancy (category D -- known teratogenic risk)
Pre-existing endometrial hyperplasia or uterine cancer
Severe hepatic impairment
Known or suspected prostate cancer
Breast cancer in males
Pregnancy or planned pregnancy (teratogenic risk)
Active liver disease or significant hepatic impairment
Pre-existing severe dyslipidemia or cardiovascular disease
Hypersensitivity to turinabol or related compounds
Research Evidence
Tamoxifen Turinabol
Status FDA Approved Moderate Research
References 5 studies 5 studies
Latest — June 2023
FDA Approved Yes No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.